Business Description
Egyptian International Pharmaceutical Investments
ISIN : EGS38081C013
Compare
Compare
Traded in other countries / regions
PHAR.Egypt IPO Date
1995-09-27Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.14 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 1.15 | |||||
| Debt-to-EBITDA | 3.09 | |||||
| Interest Coverage | 3.38 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.16 | |||||
| Beneish M-Score | -1.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.6 | |||||
| 3-Year EBITDA Growth Rate | 24 | |||||
| 3-Year EPS without NRI Growth Rate | 15.7 | |||||
| 3-Year Book Growth Rate | 8.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 22.51 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.47 | |||||
| 9-Day RSI | 37.7 | |||||
| 14-Day RSI | 40.83 | |||||
| 6-1 Month Momentum % | 29.44 | |||||
| 12-1 Month Momentum % | 87.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.94 | |||||
| Quick Ratio | 1.15 | |||||
| Cash Ratio | 0.24 | |||||
| Days Inventory | 281.42 | |||||
| Days Sales Outstanding | 77.95 | |||||
| Days Payable | 23.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.56 | |||||
| Dividend Payout Ratio | 0.24 | |||||
| 3-Year Dividend Growth Rate | -21.1 | |||||
| Forward Dividend Yield % | 4.63 | |||||
| 5-Year Yield-on-Cost % | 1.9 | |||||
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | -11.17 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.64 | |||||
| Operating Margin % | 25.08 | |||||
| Net Margin % | 15.74 | |||||
| FCF Margin % | -42.05 | |||||
| ROE % | 22.35 | |||||
| ROA % | 9.55 | |||||
| ROIC % | 13.27 | |||||
| ROC (Joel Greenblatt) % | 30.35 | |||||
| ROCE % | 25.88 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 7.17 | |||||
| PE Ratio without NRI | 6.71 | |||||
| Shiller PE Ratio | 8.79 | |||||
| PS Ratio | 1.15 | |||||
| PB Ratio | 1.51 | |||||
| Price-to-Tangible-Book | 1.51 | |||||
| Price-to-Operating-Cash-Flow | 81.47 | |||||
| EV-to-EBIT | 7.21 | |||||
| EV-to-EBITDA | 6.74 | |||||
| EV-to-Forward-EBITDA | 4.82 | |||||
| EV-to-Revenue | 2.03 | |||||
| EV-to-Forward-Revenue | 1.58 | |||||
| EV-to-FCF | -4.95 | |||||
| Price-to-Median-PS-Value | 0.43 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.53 | |||||
| Price-to-Graham-Number | 0.67 | |||||
| Earnings Yield (Greenblatt) % | 13.85 | |||||
| FCF Yield % | -34.26 | |||||
| Forward Rate of Return (Yacktman) % | 5.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Egyptian International Pharmaceutical Investments Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil E£) | 5,231.666 | ||
| EPS (TTM) (E£) | 6.014 | ||
| Beta | 0 | ||
| Volatility % | 33.99 | ||
| 14-Day RSI | 40.83 | ||
| 14-Day ATR (E£) | 1.969574 | ||
| 20-Day SMA (E£) | 45.3 | ||
| 12-1 Month Momentum % | 87.2 | ||
| 52-Week Range (E£) | 24.5 - 53.49 | ||
| Shares Outstanding (Mil) | 148.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Egyptian International Pharmaceutical Investments Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Egyptian International Pharmaceutical Investments Stock Events
| Event | Date | Price(E£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Egyptian International Pharmaceutical Investments Frequently Asked Questions
What is Egyptian International Pharmaceutical Investments(CAI:PHAR)'s stock price today?
The current price of CAI:PHAR is E£43.18. The 52 week high of CAI:PHAR is E£53.49 and 52 week low is E£24.50.
When is next earnings date of Egyptian International Pharmaceutical Investments(CAI:PHAR)?
The next earnings date of Egyptian International Pharmaceutical Investments(CAI:PHAR) is .
Does Egyptian International Pharmaceutical Investments(CAI:PHAR) pay dividends? If so, how much?
The Dividend Yield %  of Egyptian International Pharmaceutical Investments(CAI:PHAR) is 3.56% (As of Today), Highest Dividend Payout Ratio of Egyptian International Pharmaceutical Investments(CAI:PHAR) was 0.81. The lowest was 0.24. And the median was 0.58. The  Forward Dividend Yield % of Egyptian International Pharmaceutical Investments(CAI:PHAR) is 4.63%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers